Nanovibronix (NASDAQ:FEED – Get Free Report) is one of 29 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its competitors? We will compare Nanovibronix to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.
Profitability
This table compares Nanovibronix and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Nanovibronix Competitors | -672.41% | -133.75% | -59.01% |
Institutional and Insider Ownership
16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 1.4% of Nanovibronix shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nanovibronix | $2.56 million | -$3.70 million | -0.07 |
| Nanovibronix Competitors | $61.14 million | -$32.15 million | 4.36 |
Nanovibronix’s competitors have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a summary of current recommendations and price targets for Nanovibronix and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Nanovibronix Competitors | 77 | 77 | 158 | 6 | 2.29 |
As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 37.72%. Given Nanovibronix’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Nanovibronix has less favorable growth aspects than its competitors.
Volatility & Risk
Nanovibronix has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s competitors have a beta of 1.76, indicating that their average stock price is 76% more volatile than the S&P 500.
Summary
Nanovibronix competitors beat Nanovibronix on 8 of the 13 factors compared.
Nanovibronix Company Profile
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
